General MedicationsORALGeneric
UPADACITINIB
UPADACITINIB
Standard Dose
30MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary
Approval overview UPADACITINIB is listed in Drugs@FDA under application 218866 (ANDA).
Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient UPADACITINIB Form and strength TABLET;ORAL - 30MG Sponsor AUROBINDO PHARMA LTD Submission history Latest submission status date: 2025-01-03 00:00:00.
Structured Monograph
Clinical summary
Approval overview UPADACITINIB is listed in Drugs@FDA under application 218866 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient UPADACITINIB Form and strength TABLET;ORAL - 30MG Sponsor AUROBINDO PHARMA LTD Submission history Latest submission status date: 2025-01-03 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: None (Tentative Approval)
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.